共 125 条
[1]
Callahan MK(2013)At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy J Leukoc Biol. 94 41-53
[2]
Wolchok JD(2008)Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens J Clin Oncol. 26 4973-4980
[3]
Slingluff CL(2013)A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602) Clin Cancer Res. 19 4228-4238
[4]
Petroni GR(2011)Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma N Engl J Med. 364 2119-2127
[5]
Olson W(2004)Assessment of the toxicities of systemic low-dose interleukin-2 administered in conjunction with a melanoma peptide vaccine J Immunother. 27 380-388
[6]
Slingluff CL(2005)Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2 J Immunother. 28 412-419
[7]
Lee S(1994)Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response Cancer Res. 54 3342-3345
[8]
Zhao F(2005)Th2-associated local reactions to the acellular diphtheria–tetanus–pertussis vaccine in 4- to 6-year-old children Infect Immun. 73 8130-8135
[9]
Schwartzentruber DJ(2010)Immunogenicity for CD8 J Immunother. 33 630-638
[10]
Lawson DH(2013) and CD4 Cancer Immunol Immunother. 62 1149-1159